Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 5/2018

01-09-2018 | Rapid Communication

LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-β1 and downregulating PHGDH

Authors: Qing Li, Haifeng Gao, Shuyan Zhou, Yuting Liao

Published in: Breast Cancer | Issue 5/2018

Login to get access

Abstract

Objective

To investigate the role of lncRNA PlncRNA-1 in the pathogenesis of breast cancer.

Methods

A total of 78 patients with breast cancer as well as 48 healthy females were included in this study. Expression in tumor tissues and adjacent healthy tissues of breast cancer patients, as well as in breast tissues and serum of both patients and healthy control was detected by qRT-PCR. Cell proliferation was detected by CCK-8 assay, and cell apoptosis was tested by MTT assay. PlncRNA-1 overexpression cell lines were constructed and the effects on TGF-β1 as well as phosphoglycerate dehydrogenase (PHGDH) were explored by western blot.

Results

Expression levels of PlncRNA-1 were significantly lower in tumor tissues than those in adjacent healthy tissues. Significantly lower expression levels of PlncRNA-1 were also found in breast cancer patients than those in healthy controls in both breast tissue and serum. Upregulation of PlncRNA-1 promoted the expression of TGF-β1, but inhibited the expression of PHGDH. LncRNA PlncRNA-1 overexpression reduced the proliferation rate, but increased the apoptosis rate of breast cancer cells, while treatment with TGF-β inhibitor reduced those effects of PlncRNA-1 overexpression.

Conclusion

LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-β1 and downregulating PHGDH.
Literature
1.
Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.CrossRefPubMed
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Ellis LM, Hicklin D. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15:7471–8.CrossRefPubMed
4.
Shah NS. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis J CDC. 2011;17(3):510–3.
5.
Yang X, Gao L, Guo X, et al. A network based method for analysis of lncRNA-disease associations and prediction of lncRNAs implicated in diseases. PLoS One. 2014;9(1):e87797.CrossRefPubMedPubMedCentral
6.
Cui Z, Ren S, Lu J, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. In: Urologic oncology: seminars and original investigations. Elsevier, 2013, vol. 31, no. 7, pp. 1117–23.
7.
Wang CM, Wu QQ, Li SQ, et al. Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. Dig Dis Sci. 2014;59(3):591–7.CrossRefPubMed
8.
Li J, Ballim D, Rodriguez M, et al. The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem. 2014;289(51):35633–43.CrossRefPubMedPubMedCentral
9.
Jeon WK, Choi J, Park SJ, et al. The proinflammatory LTB4/BLT1 signal axis confers resistance to TGF-β1-induced growth inhibition by targeting Smad3 linker region. Oncotarget. 2015;6(39):41650.CrossRefPubMedPubMedCentral
10.
Dong L, Ni J, Hu W, et al. Upregulation of long non-coding RNA plncRNA-1 promotes metastasis and induces epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Physiol Biochem. 2016;38(2):836–46.CrossRefPubMed
11.
Xu N, Chen F, Wang F, et al. Clinical significance of high expression of circulating serum lncRNA RP11-445H22. 4 in breast cancer patients: a Chinese population-based study. Tumor Biology. 2015;36(10):7659–65.CrossRefPubMed
12.
13.
Bae MS, Moon WK, Chang JM, et al. Breast cancer detected with screening US: reasons for nondetection at mammography. Radiology. 2014;270(2):369–77.CrossRefPubMed
14.
Grammatikakis I, Panda AC, Abdelmohsen K, et al. Long noncoding RNAs (lncRNAs) and the molecular hallmarks of aging. Aging (Albany NY). 2014;6(12):992.CrossRef
15.
Wang J, Qiu M, Xu Y, et al. Long noncoding RNA CCAT2 correlates with smoking in esophageal squamous cell carcinoma. Tumor Biology. 2015;36(7):5523–8.CrossRefPubMed
16.
Mayfield RD. Emerging roles for ncRNAs in alcohol use disorders. Alcohol. 2017;60:31–9.
17.
Bao M, Luo H, Chen L, et al. Impact of high fat diet on long non-coding RNAs and messenger RNAs expression in the aortas of ApoE (−/−) mice. Sci Rep. 2016;6:34161.
18.
Si Y, Bai J, Wu J, et al. LncRNA PlncRNA-1 regulates proliferation and differentiation of hair follicle stem cells through TGF-β1-mediated Wnt/β-catenin signal pathway. Mol Med Rep. 2018;17(1):1191–7.PubMed
19.
Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–3.CrossRefPubMed
Metadata
Title
LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-β1 and downregulating PHGDH
Authors
Qing Li
Haifeng Gao
Shuyan Zhou
Yuting Liao
Publication date
01-09-2018
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0858-4

Other articles of this Issue 5/2018

Breast Cancer 5/2018 Go to the issue

Original Article

Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan

Letter to the Editor

Current status of postmastectomy radiation therapy in T1–2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey

Original Article

Evaluation of the dislocation and long-term sonographic detectability of a hydrogel-based breast biopsy site marker

Original Article

Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma

Original Article

The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines

Case Report

Pseudocirrhosis after chemotherapy in breast cancer, case reports
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits